Laboratory for Molecular Diagnostics
Center for Nephrology and Metabolic Disorders

Poor response to Eculizumab

Despite its great efficiency some patient do not properly respond to eculizumab. This poor response it mostly due to genetic variations in the complement C5 gene, but also other complement genes can be affected theoretically.

Systematic

Thrombotic microangiopathies
Hemolytic-Uremic Syndrome
Poor response to Eculizumab
C5
Thrombotic Thrombocytopenic Purpura

References:

1.

Nishimura J et. al. (2014) Genetic variants in C5 and poor response to eculizumab.

[^]
Update: Sept. 26, 2018